Redbiotec deal with Intercell
15.12.2011
Redbiotec, based in Zurich-Schlieren, signs exploratory study with Intercell and completion of influenza study.
Redbiotec has entered into a cooperation with Intercell AG (Vienna, Austria), in which Redbiotec will apply its proprietary technology platform rePAX™ to an undisclosed discovery area.
Influenza challenge successfully completed: For the proof-of-principle, influenza A/PR/8/34 VLPs carrying four parental proteins were tested in a mouse challenge model. Final results show that Redbiotec’s influenza-VLPs effectively protect the immunized mice against the parental challenge virus.
About Redbiotec
Redbiotec is a privately held Swiss Biopharmaceutical Company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the ETH Zurich, the company won several awards, including the renown W.A. De Vigier award.
Redbiotec uses its proprietary rePAXTM co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. The company entered the field of VLP vaccines in 2008 and currently has a pipeline in the areas of CMV, HPV and Influenza. Besides developing its own prophylactic VLP vaccine pipeline, the company also offers customized solutions in Biologics to selected Partners
Please login or sign up to comment.
Commenting guidelines